DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
1 other identifier
observational
350
12 countries
30
Brief Summary
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Longer than P75 for all trials
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 16, 2021
CompletedFirst Submitted
Initial submission to the registry
June 10, 2026
CompletedFirst Posted
Study publicly available on registry
July 21, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 30, 2032
July 21, 2026
July 1, 2026
6.7 years
June 10, 2026
July 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Resectability three weeks after PVE/HVE and 5 years overall survival
From enrolment until 5 year follow up
Secondary Outcomes (10)
Number of complications during embolization
Perioperative
Kinetic Growth Rate [%/week]
3 weeks after the embolization
Functional Growth Rate [%/week]
Three weeks after the embolization
90-day survival after embolization
90 days post-embolization / post-resection
Number of complications during surgery
Perioperative
- +5 more secondary outcomes
Study Arms (1)
PVE/HVE
This registry collects data on patients who have undergone combined portal and hepatic vein embolisation prior to major liver surgery.
Eligibility Criteria
All patients with primarily unresectable / potentially resectable liver cancer or liver metastases, who are treated with combined embolization of both portal and hepatic veins (PVE/HVE) in order to increase future liver remnant before resection.
You may qualify if:
- Patients who have undergone PVE/HVE or technical variations on this procedure
- Years and older
- Men and women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (31)
Rush University Medical Center
Chicago, Illinois, 60612, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Monash Medical Centre
Clayton, Victoria, 3168, Australia
MedUni Wien
Vienna, State of Vienna, 1090, Austria
Social Center South (Klinik Favoriten)
Vienna, State of Vienna, 1100, Austria
UZ Antwerpen
Edegem, Antwerpen, 2650, Belgium
Erasmus Hospital
Anderlecht, Brussels Capital, 1070, Belgium
CHU de Liège
Liège, Liège, 4000, Belgium
UZ Gent
Ghent, Oost-Vlaanderen, 9000, Belgium
Juravinski Hospital and Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
McGill University Health Centre
Montreal, Quebec, H3G 1A4, Canada
University Hospital Aachen (Uniklinik RWTH Aachen)
Aachen, North Rhine-Westphalia, 52074, Germany
Klinikum Saarbrücken
Saarbrücken, Saarland, 66119, Germany
Universitätsklinikum Halle
Halle, Saxony-Anhalt, 06120, Germany
MUMC+
Maastricht, Limburg, 6229HX, Netherlands
Amsterdam UMC
Amsterdam, North Holland, 1105 AZ, Netherlands
Universitair Medisch Centrum Groningen
Groningen, Provincie Groningen, 9713 GZ, Netherlands
Leids Universitair Medisch Centrum
Leiden, South Holland, 2333, Netherlands
Erasmus MC
Rotterdam, South Holland, 3015 GD, Netherlands
Auckland City Hospital
Grafton, Auckland, 1023, New Zealand
Oslo University Hospital
Oslo, Oslo, 0424, Norway
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
Vall d'Hebron University Hospital
Barcelona, Barcelona, 08035, Spain
Karolinska University Hospital
Stockholm, Stockholm County, 17176, Sweden
University Hospital Linköping
Linköping, Östergötland County, 581 85, Sweden
Klinik Hirslanden
Zurich, Canton of Zurich, 8032, Switzerland
Aintree University Hospital
Liverpool, Merseyside, L9 7AL, United Kingdom
Newcastle upon Tyne Hospitals
Newcastle upon Tyne, North East England, NE7 7DN, United Kingdom
Queen Elizabeth Hospital
Birmingham, West Midlands, B15 2GW, United Kingdom
Related Publications (8)
James S, van der Leij C, van Dam RM, Detry O. Liver venous deprivation before major hepatectomy-promising but still a work in progress. Hepatobiliary Surg Nutr. 2026 Feb 1;15(1):10. doi: 10.21037/hbsn-2025-560. Epub 2026 Jan 12. No abstract available.
PMID: 41676779BACKGROUNDJames S, Smits J, van der Velden AL, Simon SR, Korenblik R, Dewulf MJL, van Dam RM, van der Leij C; DRAGON Trials Collaborative. Invited Commentary on "CIRSE Standards of Practice on Portal Vein Embolization and Double Vein Embolization/Liver Venous Deprivation". Cardiovasc Intervent Radiol. 2024 Sep;47(9):1311-1312. doi: 10.1007/s00270-024-03815-9. Epub 2024 Jul 29. No abstract available.
PMID: 39078494BACKGROUNDKorenblik R, Heil J, Smits J, James S, Olij B, Bechstein WO, Bemelmans MHA, Binkert CA, Breitenstein S, Williams M, Detry O, Dewulf MJL, Dili A, Grochola LF, Grote J, Heise D, Kalil JA, Metrakos P, Neumann UP, Pappas SG, Pennetta F, Schnitzbauer AA, Tasse JC, Winkens B, Olde Damink SWM, van der Leij C, Schadde E, van Dam RM; DRAGON trials collaborative. Liver regeneration after portal and hepatic vein embolization improves overall survival compared with portal vein embolization alone: mid-term survival analysis of the multicentre DRAGON 0 cohort. Br J Surg. 2024 Apr 3;111(4):znae087. doi: 10.1093/bjs/znae087.
PMID: 38662462BACKGROUNDKorenblik R, van der Leij C, van Dam RM. Reply to: Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant Hypertrophy-The Road Towards Level One Evidence. Cardiovasc Intervent Radiol. 2023 Jan;46(1):166-167. doi: 10.1007/s00270-022-03271-3. Epub 2022 Sep 20. No abstract available.
PMID: 36127520BACKGROUNDKorenblik R, van Zon JFJA, Olij B, Heil J, Dewulf MJL, Neumann UP, Olde Damink SWM, Binkert CA, Schadde E, van der Leij C, van Dam RM; DRAGON Trials Collaborative. Resectability of bilobar liver tumours after simultaneous portal and hepatic vein embolization versus portal vein embolization alone: meta-analysis. BJS Open. 2022 Nov 2;6(6):zrac141. doi: 10.1093/bjsopen/zrac141.
PMID: 36437731BACKGROUNDKorenblik R, Olij B, Aldrighetti LA, Hilal MA, Ahle M, Arslan B, van Baardewijk LJ, Baclija I, Bent C, Bertrand CL, Bjornsson B, de Boer MT, de Boer SW, Bokkers RPH, Rinkes IHMB, Breitenstein S, Bruijnen RCG, Bruners P, Buchler MW, Camacho JC, Cappelli A, Carling U, Chan BKY, Chang DH, Choi J, Font JC, Crawford M, Croagh D, Cugat E, Davis R, De Boo DW, De Cobelli F, De Wispelaere JF, van Delden OM, Delle M, Detry O, Diaz-Nieto R, Dili A, Erdmann JI, Fisher O, Fondevila C, Fretland A, Borobia FG, Gelabert A, Gerard L, Giuliante F, Gobardhan PD, Gomez F, Grunberger T, Grunhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess GF, Hoffmann MH, Iezzi R, Imani F, Nguyen J, Jovine E, Kalff JC, Kazemier G, Kingham TP, Kleeff J, Kollmar O, Leclercq WKG, Ben SL, Lucidi V, MacDonald A, Madoff DC, Manekeller S, Martel G, Mehrabi A, Mehrzad H, Meijerink MR, Menon K, Metrakos P, Meyer C, Moelker A, Modi S, Montanari N, Navines J, Neumann UP, Peddu P, Primrose JN, Qu X, Raptis D, Ratti F, Ridouani F, Rogan C, Ronellenfitsch U, Ryan S, Sallemi C, Moragues JS, Sandstrom P, Sarria L, Schnitzbauer A, Serenari M, Serrablo A, Smits MLJ, Sparrelid E, Spuntrup E, Stavrou GA, Sutcliffe RP, Tancredi I, Tasse JC, Udupa V, Valenti D, Fundora Y, Vogl TJ, Wang X, White SA, Wohlgemuth WA, Yu D, Zijlstra IAJ, Binkert CA, Bemelmans MHA, van der Leij C, Schadde E, van Dam RM. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. Cardiovasc Intervent Radiol. 2022 Sep;45(9):1391-1398. doi: 10.1007/s00270-022-03176-1. Epub 2022 Jul 5.
PMID: 35790566BACKGROUNDChang X, Korenblik R, Olij B, Knapen RRMM, van der Leij C, Heise D, den Dulk M, Neumann UP, Schaap FG, van Dam RM, Olde Damink SWM. Influence of cholestasis on portal vein embolization-induced hypertrophy of the future liver remnant. Langenbecks Arch Surg. 2023 Jan 21;408(1):54. doi: 10.1007/s00423-023-02784-w.
PMID: 36680689BACKGROUNDHeil J, Korenblik R, Heid F, Bechstein WO, Bemelmans M, Binkert C, Bjornsson B, Breitenstein S, Detry O, Dili A, Dondelinger RF, Gerard L, Gimenez-Maurel T, Guiu B, Heise D, Hertl M, Kalil JA, Klein JJ, Lakoma A, Neumann UP, Olij B, Pappas SG, Sandstrom P, Schnitzbauer A, Serrablo A, Tasse J, Van der Leij C, Metrakos P, Van Dam R, Schadde E. Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis. Br J Surg. 2021 Jul 23;108(7):834-842. doi: 10.1093/bjs/znaa149.
PMID: 33661306BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ronald Van Dam, Dr.
Maastricht Universitair Medisch Centrum
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2026
First Posted
July 21, 2026
Study Start
March 16, 2021
Primary Completion (Estimated)
November 30, 2027
Study Completion (Estimated)
November 30, 2032
Last Updated
July 21, 2026
Record last verified: 2026-07